Pt underwent autologous hpc, apheresis cellular therapy product (ctp) collection on (b)(6) 2019.The ctp was received into the hematopoietic stem cell lab (hscl) on (b)(6) 2019 and benched overnight for processing the next morning.Processing of the ctp was initiated on (b)(6) 2019.The ctp was centrifuged per protocol for volume reduction in preparation for cryopreservation.After centrifugation had completed and upon opening the centrifuge to obtain the product from the centrifuge bucket, the bmt lab technologist discovered that the majority of the plasma had leaked from the transfer pack bag into the plastic recovery bag containing the transfer pack suggesting a breach in the transfer pack bag, at the level of the plasma cell separation.No leakage of the product cells out of the transfer pack was observed.The bmt lab technologist initiated cell rescue measures, transferred the product into a secondary 600 ml transfer pack, and completed processing and cryopreservation of the product without incident.Product sterility will be monitored through pre and post-process sterility testing.For the safety of the pt, the hscl lab director requested that the pt undergo a second hpc, apheresis ctp collection.An investigation of the incident was initiated to determine the root cause of the integrity failure.Upon initial visual examination of the transfer pack, no breach in the transfer pack material could be identified.A small volume of water was dispensed into the transfer pack and slight pressure applied to the bag.Upon applying pressure to the transfer pack, fluid was found to be leaking from a pin hole on the lower left near side of the bag.The pin hole could not be visualized without the use of fluid and pressure.The affected lot of transfer pack has been in use for months.This appears to be an isolated incident.Fda safety report id# (b)(4).
|